

Curriculum vitae

Prof.ssa Carmen Fava

Personal details

Born in Turin, Italy

Nationality: Italian

Email: carmen.fava@unito.it

ORCID ID: <https://orcid.org/0000-0002-4896-981X>; Scopus ID: 24777922700 ; Researcher ID: J-9494-2018

Educations

- 14/4/2003: Master Degree in Medicine at University of Turin. Votation: 110/110 con lode e dignità di stampa;
- 07/01/2009: Specialization in Internal Medicine at the University of Turin. Votation: 70/70 e lode;
- 26/02/2014: PhD in Experimental Medicine and Therapy. Thesis Title: "Evaluation of Tyrosine Kinase Inhibitor Pharmacokinetic Determinants in Patients Affected by Chronic Myeloid Leukemia";
- Since April 2014 Assistant Professor at the Department of Clinical and Biological Sciences, University of Turin.

Professional experiences and current position

- Since 2003 until July 2016 clinical activity at the Division of Internal Medicine-Haematology of the S. Luigi Hospital, Orbassano (TO), Italy;
- July 2007-July 2008: Post-doc-Fellowship at the Department of Leukemia-MD Anderson Cancer Center, Houston (Texas);
- Since April 2014 Assistant Professor of Haematology at the Department of Clinical and Biological Sciences, University of Turin;
- Since July 2016 clinical activity at the Division of Haematology of Ordine Mauriziano Hospital, Turin, Italy;
- Since December 2021 Associate Professor at the Department of Clinical and Biological Sciences, University of Turin;
- Coordinator of National studies on Leukemia;
- Member of the European Leukemia Network;
- Member of the Association of Italian-Brazilian Haematologists;
- Member of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD)

Honors

- Award for the best degree thesis in Medicine and Surgery, Faculty of Medicine and Surgery, University of Turin, Sede S. Luigi (academic year 2001/2002). Thesis title: "Second tumors after bone marrow transplantation in childhood: AIEOP National Study";
- Novartis Award for the best abstract presented on Ph+ Myeloproliferatives at the 45th SIE National Congress: "C. Fava, E. Gottardi, P. Berchialla, G. Rege-Cambrin, M. Varotto, F. Daraio, F. Crasto, R. Lorenzatti, A. Volpengo, C. Fantino, N. Dani, D. Barberio, I. Dogliotti, G. Saglio. Comparison of droplet digital PCR and standard PCR in Chronic Myeloid Leukemia patients in MR4. Haematologic (SIE) 2015; 100(s3): P187

Teaching activity:

- Since 2014 Professor of Haematology/MED015 in the course of Medical Degree, University of Turin;
- Since 2016 Professor in the course of PhD in Experimental Medicine and Therapy

Research main topics

- Treatment discontinuation of patients with Ph+ Chronic Myeloid Leukemia
- Digital PCR for MRD detection in Ph+ Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Standardization of Molecular Analysis by q-PCR for Ph+ Acute Lymphoblastic Leukemia
- Study of the pathophysiology of Ph+ and Ph- Myeloproliferative Disorders

Main projects as PI:

- Observational Study in Adult Patients with Chronic Myeloid Leukemia who discontinue Tyrosine Kinase Inhibitors in Italy (Italy-TFR).
- Interaction between gut microbiota and tyrosine kinase inhibitors in defining the clinical outcomes of patients with Chronic Myeloid Leukemia.
- Observational study in myelofibrosis patients: chasing role of inflammation and autoimmunity in pathogenesis, development and complications.
- Survey of CML patient expectations of the COVID 19 vaccination program.
- Evaluation of the prognostic value of digital PCR in patients with chronic myeloid leukemia who suspend treatment
- Standardization of BCR-ABL p190 molecular analysis
- Ponatinib survey: retrospective evaluation of Italian patients included in the compassionate use program or according to law 648/96

- Analysis of BCR-ABL levels by droplet digital PCR (ddPCR) in relation to patients enrolled in the clinical study "A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year: DANTE study".
- Development and validation of one or more diagnostic kits for the molecular typing of onco-haematological patients.

Bibliometry (2006-present) (www.scopus.com)

- h-index in the last 15 years: 27
- Number of articles in the last 10 years: 68
- Number of citations in the last 15 years: 2784

Publications

1. D. Ferrero, EM. Pogliani, G. Rege Cambrin, **C. Fava**, G. Mattioli, C. Della casa, E. Campa, P. Perfetti, M. Fumagalli, M. Boccadoro. Corticosteroids can reserve severe imatinib-induced hepatotoxicity. *Haematologica*. **2006** Jun;91(6 Suppl):ECR27. PMID: 16785130 [PubMed - indexed for MEDLINE]. ISSN 15928721. **IF 5.032**;
2. Capobianco M, Malucchi S, Ulisciani S, **Fava C**, Cambrin GR, Avonto L, Saglio G, Bertolotto A. Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis. *Neurol Sci*. **2008** Jun;29(3):185-7. doi: 10.1007/s10072-008-0934-1. Epub 2008 Jul 9. PMID: 18612769. ISSN 1590-1874. **IF 1.435**;
3. **Carmen Fava**, Jorge Cortes. Philadelphia-Negative Acute Myeloid Leukemia With New Chromosomal Abnormalities Developing After First-Line Imatinib Treatment For Chronic Phase Chronic Myeloid Leukemia. *Am J Hematol*. **2008** Sep;83(9):755. doi: 10.1002/ajh.21230. PMID: 1861555. ISSN 0361-8609. **IF 2.126**;
4. Verma D, **Fava C**, Kantarjian H, Cortes J. Complexity of BCR-ABL kinase domain mutations in chronic myeloid leukemia in response to Tyrosine Kinase Inhibitors. *Am J Hematol*. **2009** Apr;84(4):256-7. doi: 10.1002/ajh.21366. PMID: 19260121. ISSN 0361-8609. **IF 2.610**;
5. **Fava C**, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Failure to achieve a complete hematologic response at the time of achievement of a major cytogenetic response with second generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. *Blood*. **2009** May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12. PMID: 19282457. ISSN 0006-4971. **IF 10.555**;
6. **Carmen Fava** and Jorge Cortes. Optimizing first-line therapy for patients with chronic myeloid leukemia. *Semin Hematol*. **2009** Apr; 46(2 Suppl 3): S5-10. PMID: 19621543. ISSN 0037-1963. **IF 2.703**;
7. Giuseppe Saglio and **Carmen Fava**. Inhibition of SDF-1/CXCR4 for the cure of BCR-ABL positive chronic myeloid leukemia. *Leuk Lymphoma*. **2009** Oct; 50(10): 1564-5. doi: 10.1080/10428190903216853. PMID: 19757319. ISSN 1042-8194. **IF 2.397**;
8. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, **Fava C**, Intermesoli T, Rege Cambrin G, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. *Blood*. **2009** Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. PMID: 19822896. ISSN 0006-4971. **IF 10.555**;
9. **Fava C**, Kantarjian H, Cortes J, Jabbour E. Development and targeted use of Nilotinib in Chronic Myeloid Leukemia. *Drug Des Devel Ther*. **2009** Feb 6;2:233-43. PMID: 19920910. ISSN 11778881.
10. Elias Jabbour, **Carmen Fava**, Hagop Kantarjian. Advances in Biology and Therapy of Patients with Chronic Myeloid Leukemia. *Best Pract Res Clin Haematol*. **2009** Sep;22(3):395-407. doi: 10.1016/j.beha.2009.09.002. Review. PMID: 19959090. ISSN 1521-6926. **IF 3.134**;
11. **Carmen Fava**, Jorge Cortes, Hagop Kantarjian, Elias Jabbour. Standard management of patients with chronic myeloid leukemia. *Clin Lymphoma Myeloma*. **2009**;9 Suppl 4:S382-90. doi: 10.3816/CLM.2009.s.038. Review. PMID: 20007107. ISSN 1557-9190. **IF 1.130**;
12. Saglio G., **Fava C**. Chronic myelogenous leukemia: The present and the future of the TKI therapy [Leucemia mieloide cronica: O presente e o futuro dos inibidores de tirosino quinase]. *Revista Brasileira de Hematologia e Hemoterapia*. **2009**; 31(2):57-60. ISSN 15168484;
13. François-Xavier Mahon, Mathieu Molimard, Kajetana Foryciarz, Andrea Davies, **Carmen Fava**, David Friedecky, Eberhard Schleyer, Peter Schuld, and François Guilhot. Imatinib blood level testing: current perspectives and key questions. *European Journal of Haematology*. **2010**;
14. Falchi L, Rege-Cambrin G, **Fava C**, Donti E, Luzi D, Giugliano E, Gubbiotti M, Schippa M, Liberati AM. Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution. *Cancer Genet Cytogenet*. **2010** Jun;199(2):139-42. doi: 10.1016/j.cancergencyto.2010.02.008. PMID: 20471518. ISSN 0165-4608. **IF 1.551**;
15. Santos FP, Kantarjian H, **Fava C**, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. *Br J Haematol*. **2010** Aug;150(3):303-12. doi:10.1111/j.1365-2141.2010.08245.x. Epub 2010 Jun 10. Erratum in: *Br J Haematol*. 2011 Nov;155(3):409. PMID: 20553275. ISSN 0007-1048. **IF 4.942**;

16. Fava C, Saglio G. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? *Semin Hematol.* **2010** Oct;47(4):319-26. doi: 10.1053/j.seminhematol. 2010.06.001. Review. PMID: 20875548. ISSN 0037-1963. **IF 3.038**;
17. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, **Fava C**, Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosini MA, Leeksa O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. *J Natl Cancer Inst.* **2011** Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21. Erratum in: *J Natl Cancer Inst.* 2016 Sep;108(9). pii: djw211. doi: 10.1093/jnci/djw211. Piazza, Rocco [added]. PMID:21422402. ISSN 0027-8874. **IF 13.757**;
18. Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, **Fava C**, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G. Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. *Haematologica.* **2011** Oct;96(10):1457-61. doi: 10.3324/haematol.2011.041251. Epub 2011 Jun 17. PMID: 21685471. ISSN 0390-6078. **IF 6.424**;
19. Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, **Fava C**, Rosti G, Alimena G. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. *Leuk Res.* **2011** Sep;35(9):1164-9. doi: 10.1016/j.leukres.2011.05.015. Epub 2011 Jun 25. PMID: 21705080. ISSN 0145-2126. **IF 2.923**;
20. Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A, Albano F, **Fava C**, Vannucchi AM. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. *Blood.* **2011** Sep 22;118(12):3445-6. Doi:10.1182/blood-2011-07-365007. PMID: 21940831. ISSN 0006-4971. **IF 9.898**;
21. Pirro E, De Francia S, De Martino F, **Fava C**, Ulisciani S, Cambrin GR, Racca S, Saglio G, Di Carlo F. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. *J Chromatogr Sci.* **2011** Nov-Dec;49(10):753-7. doi: 10.1093/chrscl/49.10.753. PMID: 22080802. ISSN 0021-9665. **IF 0.884**;
22. D'Avolio A, Simiele M, De Francia S, Ariaudo A, Baietto L, Cusato J, **Fava C**, Saglio G, Di Carlo F, Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). *J Pharm Biomed Anal.* **2012** Feb 5;59:109-16. doi: 10.1016/j.jpba.2011.10.003. Epub 2011 Oct 14. PMID:22036594. ISSN 0731-7085. **IF 2.947**;
23. Saglio G, **Fava C**. Practical monitoring of chronic myelogenous leukemia: when to change treatment. *J Natl Compr Canc Netw.* **2012** Jan;10(1):121-9. Review. doi: 10.6004/jncn.2012.001. PMID: 22223872. ISSN 1540-1405. **IF 5.112**;
24. **Fava C**, Kantarjian H, Cortes J. Molecular resistance: an early indicator fortreatment change? *Clin Lymphoma Myeloma Leuk.* **2012** Apr; 12(2):79-87. doi:10.1016/j.clml.2011.12.004. Epub 2012 Jan 28. Review. PMID: 22285607. ISSN 2152-2650. **IF 1.667**;
25. **Fava C**, Rege-Cambrin G, Saglio G. Chronic myeloid leukemia: state of the art in 2012. *Curr Oncol Rep.* **2012** Oct;14(5):379-86. doi: 10.1007/s11912-012-0253-9. Review. PMID: 22821153. 1523-3790. **IF 3.327**;
26. Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, **Fava C**, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. *Ann Hematol.* **2013** Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10. PMID: 23053188. ISSN 0939-5555. **IF 2.396**;
27. Russo Rossi AV, Breccia M, Abruzzese E, Castagnetti F, Luciano L, Gozzini A, Annunziata M, Martino B, Stagno F, Cavazzini F, Tiribelli M, Visani G, Pregno P, Musto P, **Fava C**, Sgherza N, Albano F, Rosti G, Alimena G, Specchia G. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. *Haematologica.* **2013** Mar; 98(3):399-403. doi: 10.3324/haematol.2012.064337. Epub 2012 Jul 16. PMID: 22801965. ISSN 0390-6078. **IF 5.868**;
28. Latagliata R, Breccia M, **Fava C**, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. *Hematol Oncol.* **2013** Jun;31(2):363-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Erratum in: *Hematol Oncol.* 2013 Sep;31(3):169. PMID: 22815278. ISSN 0278-0232. **IF 2.355**;
29. Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, **Fava C**, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. *Blood.* **2013** Jun 27;121(26):5138-44. doi: 10.1182/blood-2013-01-480194. Epub 2013 May 15. Erratum in: *Blood.* 2014 May 1;123(18):2902. Bergamaschi, Michela [corrected to Bergamaschi, Micaela]. PMID: 23678005. ISSN 0006-4971. **IF 9.775**;
30. Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Baratè C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, **Fava C**,

- Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. *Leukemia*. **2013** Jul;27(7):1511-9. doi: 10.1038/leu.2013.51. Epub 2013 Feb 18. PMID: 23417029. ISSN 0887-6924. **IF 9.379**;
31. Latagliata R, Ferrero D, Iurlo A, Cavazzini F, Castagnetti F, Abruzzese E, **Fava C**, Breccia M, Annunziata M, Stagno F, Tiribelli M, Binotto G, Mansueto G, Gozzini A, Russo S, Cavalli L, Montefusco E, Gugliotta G, Cedrone M, Russo Rossi A, Avanzini P, Pregno P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Storti S, D'Addosio A, Rege-Cambrin G, Luciano L, Alimena G. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. *Drugs Aging*. **2013** Aug;30(8):629-37. doi: 10.1007/s40266-013-0088-6. PMID: 23681399. ISSN 1170-229X. **IF 2.503**;
 32. **Fava C**, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant. *Clin Lymphoma Myeloma Leuk*. **2013** Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. No abstract available. PMID: 24290212. ISSN 2152-2650. **IF 1.929**; TC Scopus 4; **BEST TC 4; Q3 Scopus; Q3 WOS**
 33. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, **Fava C**, Calcagno A, Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. *Ther Drug Monit*. **2014** Jun;36(3):410-2. doi: 10.1097/FTD.0000000000000013. PMID: 24342895. ISSN 0163-4356. **IF 2.376**;
 34. Morotti A, Panuzzo C, **Fava C**, Saglio G. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. *Expert Opin Biol Ther*. **2014** Mar;14(3):287-99. doi: 10.1517/14712598.2014.867323. Epub 2014 Jan 3. Review. PMID: 24387320. ISSN 1471-2598. **IF 3.743**;
 35. Cardinale L, Asteggiano F, Moretti F, Torre F, Ulisciani S, **Fava C**, Rege-Cambrin G. Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome. *World J Radiol*. **2014** Aug 28;6(8):583-8. doi: 10.4329/wjr.v6.i8.583. Review. PMID: 25170395.
 36. Morotti A, Panuzzo C, Crivellaro S, Carrà G, **Fava C**, Guerrasio A, Pandolfi PP, Saglio G. BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. *Cell Cycle*. **2015**;14(7):973-9. doi: 10.1080/15384101.2015.1006970. PMID: 25608112. ISSN 1538-4101. **IF 3.952**;
 37. **Fava C**, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. *Ann Hematol*. **2015** Apr;94 Suppl 2:S123-31. doi: 10.1007/s00277-015-2321-3. Epub 2015 Mar 27. Review. PMID: 25814078. ISSN 0939-5555. **IF 3.022**;
 38. **Fava C**, Morotti A, Dogliotti I, Saglio G, Rege-Cambrin G. Update on emerging treatments for chronic myeloid leukemia. *Expert Opin Emerg Drugs*. **2015** Jun;20(2):183-96. doi: 10.1517/14728214.2015.1031217. Epub 2015 Mar 31. Review. PMID: 25826695. ISSN 1472-8214. **IF 2.120**;
 39. Morotti A, **Fava C**, Saglio G. Milestones and monitoring. *Curr Hematol Malig Rep*. **2015** Jun;10(2):167-72. doi: 10.1007/s11899-015-0258-1. Review. PMID: 25921389. ISSN 1558-8211. **IF 2.146**;
 40. Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, **Fava C**, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica*. **2015** Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. Epub 2015 Jun 25. PMID: 26113419. ISSN 0390-6078. **IF 6.671**;
 41. Rosso V, Bracco E, Pedrola R, Carturan S, Signorino E, Petiti J, Calabrese C, Nicoli P, De Gobbi M, Gaidano V, Gallo D, Ulisciani S, **Fava C**, Rege-Cambrin G, Frassonni F, Saglio G, Cilloni D. Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. *Biomark Res*. **2015** Jul 3;3:15. doi: 10.1186/s40364-015-0039-y. eCollection 2015. PMID: 26146560. ISSN 20 50-7771;
 42. Efficace F, Rosti G, Breccia M, Cottone F, Giesinger JM, Stagno F, Iurlo A, Russo Rossi A, Luciano L, Martino B, Galimberti S, Turri D, Bergamaschi M, Tiribelli M, **Fava C**, Angelucci E, Mandelli F, Baccarani M. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. *Ann Hematol*. **2016** Jan;95(2):211-9. doi: 10.1007/s00277-015-2541-6. Epub 2015 Nov 7. PMID: 26546359 ISSN 0939-5555. **IF 3.083**;
 43. Saglio G, **Fava C**. BCR-ABL1 mutation $\neq$ ponatinib resistance. *Blood*. **2016** Feb 11;127(6):666-7. doi: 10.1182/blood-2015-12-685149. No abstract available. PMID: 26869304. ISSN 0006-4971. **IF 13.164**;
 44. **Fava C**, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. *Clin Lymphoma Myeloma Leuk*. **2016** Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review. PMID: 27131622. ISSN 2152-2650. **IF 2.494**;
 45. **Fava C**, Saglio G. Ponatinib for chronic myeloid leukaemia: future perspectives. *Lancet Oncol*. **2016** May;17(5):546-7. doi:10.1016/S1470-2045(16)30064-X. Epub 2016 Apr 12. No abstract available. PMID: 27083331 ISSN 1470-2045. **IF 33.900**;
 46. Latagliata R, Stagno F, Annunziata M, Abruzzese E, Iurlo A, Guarini A, **Fava C**, Gozzini A, Bonifacio M, Sorà F, Leonetti Crescenzi S, Bocchia M, Crugnola M, Castagnetti F, Capodanno I, Galimberti S, Feo C, Porrini R, Pregno P, Rizzo M, Antolino A, Mauro E, Sgherza N, Luciano L, Tiribelli M, Russo Rossi A, Trawinska M, Vigneri P, Breccia M, Rosti G, Alimena G. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. *Neoplasia*. **2016** Sep;18(9):536-40. doi: 10.1016/j.neo.2016.07.005. PMID:27659013. ISSN 1476-5586. **IF 5.006**;
 47. Morotti A, Torti D, Carra G, Panuzzo C, Crivellaro S, Taulli R, **Fava C**, Guerrasio A, Saglio G. Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia. *Curr Drug*

Targets. **2017**;18(4):389-395. doi: 10.2174/1389450117666160608120527. Review. PMID: 27291926. ISSN 1389-4501. **IF 3.112**;

48. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, **Fava C**, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget*. **2016** Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657. PMID: 27579540. ISSN 1949-2553. **IF 5.168**;
49. Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baràtè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. *Cancer Chemother Pharmacol*. **2017** Apr;79(4):767-773. doi: 10.1007/s00280-017-3271-3. Epub 2017 Mar 13. PMID: 28289867. ISSN 0344-5704. **IF 2.808**;
50. Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, **Fava C**, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *Am J Hematol*. **2017** Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30. PMID:28466557. ISSN 0361-8609; **IF 5.303**;
51. **Fava C**, Saglio G. The biology of CML supports second-generation TKIs as frontline treatment. *Clin Adv Hematol Oncol*. **2017** Apr;15(4):302-307. No abstract available. PMID:28591106. ISSN 1543-0790;
52. Dogliotti I, **Fava C**, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G. CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. *Stem Cell Investig*. **2017** Jun 23;4:57. doi:10.21037/sci.2017.06.02. eCollection 2017. PMID: 28725653;
53. Galimberti S, Bucelli C, Arrigoni E, Baràtè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. *Oncotarget*. **2017** Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20. PMID: 29152138. ISSN 1949-2553. NO IF;
54. Lee S., Fava C., Lipton J.H., Saglio G. What should frontline treatment be in chronic myeloid leukemia? *Clinical Advances in Hematology and Oncology*. **2017**; 15 (4):302-307. ISSN 1543-0790;
55. Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, Castagnetti F, Pregno P, Sgherza N, Celesti F, Bocchia M, Gozzini A, Fava C, Cattaneo D, Crugnola M, Montefusco E, Mauro E, Capodanno I, Breccia M. Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. *Br J Haematol*. **2018** Apr;181(2):267-270. doi:10.1111/bjh.14553. Epub 2017 Feb 7. No abstract available. PMID: 28169426. ISSN 0007-1048 **IF 5.206**;
56. Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, **Fava C**, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Ann Hematol*. **2018** Jan;97(1):95-100. doi:10.1007/s00277-017-3144-1. Epub 2017 Oct 2. PMID: 28971265. ISSN 0939-5555. **IF 2.85**;
57. Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, **Fava C**, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baràtè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D. Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. *Front Oncol*. **2018** May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018. PMID: 29900128. ISSN 2234-943X. **IF 4.137**;
58. Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? *Haematologica*. **2019** May;104(5):862-864. doi:10.3324/haematol.2018.214445. PMID: 31040230; PMCID: PMC6518890. **IF 7.116**;
59. Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C, Saglio G. Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR? *Int J Mol Sci*. **2019** May 7;20(9):2249. doi: 10.3390/ijms20092249. PMID: 31067725; PMCID: PMC6540058. **IF 4.556**;
60. Rosso V, Panuzzo C, Petiti J, Carturan S, Dragani M, Andreani G, **Fava C**, Saglio G, Bracco E, Cilloni D. Reduced Expression of Sprouty1 Contributes to the Aberrant Proliferation and Impaired Apoptosis of Acute Myeloid Leukemia Cells. *J Clin Med*. **2019** Jul 4;8(7):972. doi: 10.3390/jcm8070972. PMID: 31277439; PMCID: PMC6678378. **IF 3.303**;

61. Dragani M, Andreani G, **Fava C**, Daraio F, Gottardi E, Giugliano E, Nicoli P, Rege-Cambrin G. Philadelphia-positive lymphoblastic lymphoma: a case report and review of the literature. *Stem Cell Investig.* **2019** Jul 9;6:17. doi: 10.21037/sci.2019.06.06. PMID: 31463310; PMCID: PMC6691076;
62. **Fava C**, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. *Haematologica.* 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28. PMID: 30819917; PMCID: PMC6669161. **IF 7.116**;
63. Petiti J, Rosso V, Lo Iacono M, Panuzzo C, Calabrese C, Signorino E, Pironi L, Cartellà A, Bracco E, Pergolizzi B, Beltramo T, **Fava C**, Cilloni D. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways. *J Cell Mol Med.* **2019** Jun;23(6):4349-4357. doi: 10.1111/jcmm.14326. Epub 2019 Apr 29. PMID: 31033209. **IF 4.486**;
64. Crugnola M, Castagnetti F, Breccia M, Ferrero D, Trawinska MM, Abruzzese E, Annunziata M, Stagno F, Tiribelli M, Binotto G, Bonifacio M, **Fava C**, Iurlo A, Bucelli C, Mansueto G, Gozzini A, Falzetti F, Montefusco E, Crisà E, Gugliotta G, Russo S, Cedrone M, RussoRossi A, Pregno P, Isidori A, Mauro E, Atelda R, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Galimberti S, Orlandi E, Calistri E, Bocchia M, Cavazzini F, Rege Cambrin G, Orofino N, Luciano L, Sgherza N, Rosti G, Latagliata R, Capodanno I. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. *Ann Hematol.* **2019** Oct;98(10):2329-2338. doi: 10.1007/s00277-019-03767-y. Epub **2019** Aug 7. PMID:31392461. **IF 2.904**;
65. Stella S, Gottardi EM, Favout V, Barragan Gonzalez E, Errichiello S, Vitale SR, **Fava C**, Luciano L, Stagno F, Grimaldi F, Pironi L, Sargas Simarro C, Vigneri P, Izzo B. The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias. *Int J Mol Sci.* **2019** Dec 4;20(24):6106. doi: 10.3390/ijms20246106. PMID: 31817063; PMCID: PMC6941015. **IF 4.556**;
66. Dragani M, Rege-Cambrin G, Ferrero D, Abruzzese E, Pregno P, Elena C, Cedrone M, Santoro M, Andreani G, Saglio G, **Fava C**. Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. *Leuk Lymphoma.* **2019** Dec;60(13):3330-3332. doi: 10.1080/10428194.2019.1622103. Epub 2019 Jun 4. PMID: 31161827. **IF 2.969**;
67. Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, **Fava C**, Fazi P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. *Blood Adv.* **2019** Dec 23;3(24):4280-4290. doi:10.1182/bloodadvances.2019000865. PMID: 31869412; PMCID: PMC6929396. **IF 4.91**;
68. Petiti J, Rosso V, Croce E, Franceschi V, Andreani G, Dragani M, De Gobbi M, Lunghi M, Saglio G, **Fava C**, Lo Iacono M, Cilloni D. Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia. *J Clin Med.* **2020** Jan 19;9(1):271. doi: 10.3390/jcm9010271. PMID: 31963812; PMCID: PMC7019902. **IF 4.241**;
69. Rosso V, Petiti J, Dragani M, Andreani G, Croce E, Lo Iacono M, Saglio G, **Fava C**, Cilloni D. Clone wars: co-occurrence of IDH2 R140Q and R172K in myelodysplastic syndromes. *Ann Hematol.* 2020 Apr;99(4):891-893. doi: 10.1007/s00277-020-03913-x. Epub **2020** Feb 4. PMID: 32016578. **IF 2.904**;
70. Petiti J, Dragani M1, Castelli A, Lo Iacono M1, Fantino C, Badino C, Serra A, Giugliano E, Andreani G, Rosso V, Gottardi E, RegeCambrin G, Saglio G, Cilloni D and Fava C. Characterization and monitoring by droplet digital PCR of a novel BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia. January **2020**. *Journal of Translational Science* 6(5):2020. DOI:10.15761/JTS.1000369;
71. Foà R, Bonifacio M, Chiaretti S, Curti A, Candoni A, **Fava C**, Ciccone M, Pizzolo G, Ferrara F. Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. *Br J Haematol.* 2020 Jul;190(1):e3-e5. doi: 10.1111/bjh.16758. Epub **2020** Jun 14. PMID: 32368790; PMCID: PMC7267647. **IF 6.998**;
72. Petiti J, Lo Iacono M, Dragani M, Pironi L, Fantino C, Rapanotti MC, Quarantelli F, Izzo B, Divona M, Rege-Cambrin G, Saglio G, Gottardi EM, Cilloni D, **Fava C**. Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts. *J Clin Med.* **2020** May 13;9(5):1457. doi:10.3390/jcm9051457. PMID: 32414125; PMCID: PMC7290999. **IF 4.241**;
73. Panuzzo C, Jovanovski A, Pergolizzi B, Pironi L, Stanga S, **Fava C**, Cilloni D. Mitochondria: A Galaxy in the Hematopoietic and Leukemic Stem Cell Universe. *Int J Mol Sci.* **2020** May 30;21(11):3928. doi: 10.3390/ijms21113928. PMID: 32486249; PMCID: PMC7312164. **IF 5.923**;
74. Breccia M, Abruzzese E, Bocchia M, Bonifacio M, Castagnetti F, **Fava C**, Galimberti S, Gozzini A, Gugliotta G, Iurlo A, Latagliata R, Luciano L, Pregno P, Rege-Cambrin G, Rosti G, Stagno F, Tiribelli M, Foà R, Saglio G; Campus CML working group. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in

- Italy. A campus CML survey. *Leukemia*. **2020** Aug;34(8):2260-2261. doi: 10.1038/s41375-020-0904-z. Epub 2020 Jun 18. PMID: 32555369; PMCID: PMC7301058. **IF 11.528**;
75. Petiti J, Lo Iacono M, Rosso V, Andreani G, Jovanovski A, Podestà M, Lame D, Gobbi M, **Fava C**, Saglio G, Frassoni F, Cilloni D. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. *J Cell Mol Med*. **2020** Sep;24(18):10978-10986. doi: 10.1111/jcmm.15730. Epub 2020 Aug 13. PMID: 32790151; PMCID: PMC7521327. **IF 5.31**;
 76. Dragani M, Petiti J, Rege-Cambrin G, Gottardi E, Daraio F, Caocci G, Aguzzi C, Crisà E, Andreani G, Caciolli F, **Fava C**. Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts. *Mediterr J Hematol Infect Dis*. **2020** Sep 1;12(1):e2020066. doi: 10.4084/MJHID.2020.066. PMID:32952977; PMCID: PMC7485467. **IF 2.576**;
 77. Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, **Fava C**, Fenu S, Ferrara IL, Fianchi L, Filì C, Finelli C, Gai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V. SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. *Hemasphere*. **2020** Sep 23;4(5):e483. doi:10.1097/HS9.0000000000000483. PMID: 33062948; PMCID: PMC7523798;
 78. Calabrese C, Panuzzo C, Stanga S, Andreani G, Ravera S, Maglione A, Pironi L, Petiti J, Shahzad Ali MS, Scaravaglio P, Napoli F, **Fava C**, De Gobbi M, Frassoni F, Saglio G, Bracco E, Pergolizzi B, Cilloni D. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. *Int J Mol Sci*. **2020** Oct 16;21(20):7674. doi: 10.3390/ijms21207674. PMID: 33081324; PMCID: PMC7589297. **IF 5.923**;
 79. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, **Fava C**, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol*. **2020** Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13. PMID: 32798473; PMCID: PMC7426107. **IF 18.959**;
 80. Jovanovski A, Petiti J, Giugliano E, Gottardi EM, Saglio G, Cilloni D, Fava C. Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR. *Cancers (Basel)*. **2020** Nov 6;12(11):3287. doi: 10.3390/cancers12113287. PMID:33172063; PMCID: PMC7694607. **IF 6.639**;
 81. Dragani M, Rege Cambrin G, Berchiolla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C, Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A, Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Gai V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, **Fava C**. A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. *J Clin Med*. **2020** Nov 17;9(11):3692. doi: 10.3390/jcm9113692. PMID: 33213044; PMCID: PMC7698481. **IF 4.241**;
 82. Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B, Pungolino E, Elena C, Bergamaschi M, Assouline S, Di Bona E, Gozzini A, Andrade-Campos M, Stagno F, Iurlo A, Pirola A, Fontana D, Petiti J, Bonanomi ML, Crivori P, Piazza R, **Fava C**, Gambacorti-Passerini C. Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. *Blood*. **2020** Nov 5;136(19):2237-2240. doi: 10.1182/blood.2019004371. PMID: 32518953. **IF 22.113**;
 83. Lo Iacono M, Signorino E, Petiti J, Pradotto M, Calabrese C, Panuzzo C, Caciolli F, Pergolizzi B, De Gobbi M, Rege-Cambrin G, **Fava C**, Giachino C, Bracco E, Saglio G, Frassoni F, Cilloni D. Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1. *Cancers (Basel)*. **2021** Jan 14;13(2):293. doi: 10.3390/cancers13020293. PMID: 33466839; PMCID: PMC7830713. **IF 6.639**;
 84. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, **Fava C**, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. *Antivir Ther*. **2021** Jan 18. doi:10.3851/IMP3377. Epub ahead of print. PMID: 33506810;
 85. Houshmand M, Garelo F, Stefania R, Gaidano V, Cignetti A, Spinelli M, **Fava C**, Nikougoftar Zarif M, Galimberti S, Pungolino E, Annunziata M, Luciano L, Specchia G, Bocchia M, Binotto G, Bonifacio M, Martino B, Pregno P, Stagno F, Iurlo A, Russo S, Aime S, Circosta P, Saglio G. Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. *Cancers (Basel)*. **2021** Mar 15;13(6):1311. doi: 10.3390/cancers13061311. PMID: 33804056; PMCID: PMC8000981. **IF 6.639**;
 86. **Fava C**, Bernardi S, Gottardi EM, Lorenzatti R, Galeotti L, Ceccherini F, Cordoni F, Daraio F, Giugliano E, Jovanovski A, Petiti J, Varotto M, Barberio D, Rege-Cambrin G, Berchiolla P, Sciannameo V, Malagola M, Saglio G, Russo D. Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (ThermoFisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia. *Diseases*. **2021** May 5;9(2):35. doi: 10.3390/diseases9020035. PMID: 34062996;

87. Berchialla, Paola, Giraudo, Maria Teresa, **Fava Carmen**, Ricotti, Andrea, Saglio, Giuseppe, Lorenzoni, Giulia, Sciannameo, Veronica, Urru, Sara, Prosepe, Ilaria, Lanera, Corrado, Azzolina, Danila, Gregori, Dario. To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic. Applied Sciences. 2021; 11(9):4042, 2021. **IF 2.474.**